Table 5 Subsequent chemotherapy after nivolumab (n = 55)

Subsequent chemotherapy

All patients (n = 55)

Responder (n = 18)

Non-responder (n = 37)

p

 No

31 (56%)

6 (33%)

25 (68%)

0.022

 Yes

24 (44%)

12 (67%)

12 (32%)

Treatment after nivolumab

All patients (n = 24)

Responder (n = 12)

Non-responder (n = 12)

p

 Irinotecan

15 (62%)

6 (50%)

9 (75%)

0.226

 Taxane

9 (38%)

6 (50%)

3 (25%)

0.411

 Pyrimidine analog

7 (29%)

3 (25%)

4 (33%)

0.673

 Platinum

6 (25%)

3 (25%)

3 (25%)

1

 Ramucirumab

6 (25%)

4 (33%)

2 (17%)

0.645

 Trifluridine/tipiracil

2 (8%)

2 (17%)

0 (0%)

0.411